GSK583

GSK583

Biochem/physiol Actions

GSK583 is a cell-permeable indazolylquinolinamine that acts as an ATP-competitive (IC50 = 2 & 5 nM using rat & human RIPK2, respectively) inhibitor against RIPK2 kinase activity (66.6% inhibition at 1 µM; [ATP] = 10 µM), exhibiting much reduced or no inhibitory potency against a panel of 209 other kinases ﹤34% inhibition at 1 µM; [ATP] = 10 ?M). GSK583 selectively inhibits against NOD1- and NOD2-, but not TLR2-, TLR4-, TLR7-. IL-1R-, or TNFR-dependent pro-inflammatory cytokines release (>95% inhibition vs. ﹤40% inhibition at 1 ?M using primary human monocytes stimulated with respective ligands). GSK583 effectively inhibits TNF? and IL-6 production from Crohn′s disease (CD) and ulcerative colitis (UC) patients intestinal explant cultures ex vivo (IC50 = 200 nM) and is efficacious against NOD1 ligand FK156- and NOD2 ligand MDP-induced inflammatory responses in mice and rats (10 mg/kg p.o.) in vivo.

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3575622 GSK583 white to beige 100 SIGMA-ALDRICH 2-8°C
£490.29 (exc VAT) per 25MG
-
+
3575623 GSK583 white to beige 100 SIGMA-ALDRICH 2-8°C
£150.43 (exc VAT) per 5MG
-
+